Cargando…
Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer
SRC tyrosine kinase is frequently overexpressed and activated in late-stage, poor prognosis ovarian tumours, and preclinical studies have supported the use of targeted SRC inhibitors in the treatment of this disease. The SAPPROC trial investigated the addition of the SRC inhibitor saracatinib (AZD05...
Autores principales: | McGivern, Niamh, El-Helali, Aya, Mullan, Paul, McNeish, Iain A., Paul Harkin, D., Kennedy, Richard D., McCabe, Nuala |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797008/ https://www.ncbi.nlm.nih.gov/pubmed/29435137 http://dx.doi.org/10.18632/oncotarget.23524 |
Ejemplares similares
-
Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
por: Kaye, S, et al.
Publicado: (2012) -
Exploring the benefits of in-diet versus repeated oral dosing of saracatinib (AZD0530) in chronic studies: insights into pharmacokinetics and animal welfare
por: Vasanthi, Suraj S., et al.
Publicado: (2023) -
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study
por: Oswald, Ailsa J., et al.
Publicado: (2023) -
A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease
por: Nygaard, Haakon B, et al.
Publicado: (2015) -
Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung
por: Baird, Kristin, et al.
Publicado: (2020)